Radhika A. Patel

Loss of extracellular matrix-integrin signaling switches off YAP/TEAD and lets prostate adenocarcinoma organoids turn neuroendocrine; LATS inhibition reverses it, and combined YAP, NOTCH and AR inhibition fully reprograms them.

This study evaluates Aclarubicin's safety and efficacy in pediatric cancer models, finding it effective with reduced genotoxicity and cardiotoxicity compared to doxorubicin.

This study reprograms AR-active prostate cancer to NEPC using ASCL1 and NeuroD1, revealing their role in silencing AR and altering chromatin structure.

The paper uses single-cell analysis to study how cell surface antigen expression changes in treatment-resistant prostate cancer, revealing transcriptional heterogeneity and shared gene regulatory networks between NEPC and SCLC.

This paper shows that LSD1 inhibition is effective against neuroendocrine prostate cancer (NEPC) and that combining it with YAP/TEAD inhibition enhances treatment efficacy.